Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?

Mark A. Schroeder, William Blum

Research output: Contribution to journalReview articlepeer-review

Fingerprint

Dive into the research topics of 'Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?'. Together they form a unique fingerprint.

Medicine & Life Sciences